Assessment of Adherence to and Persistence on Disease-Modifying Antirheumatic Drugs (DMARDs) in Patients With Rheumatoid Arthritis

OBJECTIVE: Biologic disease-modifying antirheumatic drugs (DMARDs) are efficacious for treating rheumatoid arthritis (RA). However, measurements of relative effectiveness, including treatment adherence and persistence, are lacking. We evaluated adherence and persistence during new episodes of use of traditional and biologic DMARDs. METHODS: Using Tennessee Medicaid databases (1995-2004), we assembled a retrospective cohort of patients diagnosed with RA, and identified new episodes of use for 12 DMARD regimens. We evaluated persistence through survival analyses, and adherence within episodes through the medication possession ratio. A risk score was included in the analyses to account for measured confounders. RESULTS: We identified 14,932 patients with RA; 6018 patients had 10,547 episodes of new use of DMARDs. Considering methotrexate as the reference and after adjustment for measured confounders, episodes of new use of sulfasalazine [adjusted hazard ratio (aHR) = 1.59; 95% confidence interval (CI) = 1.47-1.72] and infliximab alone (aHR = 1.37, 95% CI = 1.09-1.73) were more likely to be discontinued; and new episodes of etanercept (aHR = 0.82, 95% CI = 0.73-0.92) and methotrexate + adalimumab (aHR = 0.63, 95% CI = 0.48-0.84) were less likely to be discontinued. Compared with methotrexate, adherence was higher for leflunomide, infliximab, etanercept, and adalimumab and lower for sulfasalazine and all combined therapies. CONCLUSIONS: We developed an approach to assess persistence on and adherence to the most common DMARD therapies. In this large cohort, persistence and adherence to leflunomide and most biologic DMARD therapies were at least comparable to methotrexate. Adherence was lower for sulfasalazine and all combined therapies

Antirheumatic Agents · Antirheumatic drugs · Disease · Intensive care medicine · Persistence (discontinuity) · Physical therapy · Rheumatoid arthritis · Biosimilars and Bioanalytical Methods · Internal Medicine · Medication Adherence and Compliance · Medicine · Rheumatoid Arthritis Research and Therapies

• Emerging Methods in Comparative Effectiveness and Safety

  Kathleen N Lohr•Medical Care•2007

  Incluir item

• Não adesão à terapia biológica em pacientes com doenças reumáticas no Sistema Único de Saúde em Minas Gerais, Brasil

  Open Access•Clarice Gomes e Souza Dabés, Alessandra Maciel Almeida et al.•Cadernos de Saude Publica•2015

  Incluir item

• The assessment of refill compliance using pharmacy records

  Open Access•J F Steiner, Allan V Prochazka•Journal of Clinical Epidemiology•1997

  Incluir item

• The Robust Inference for the Cox Proportional Hazards Model

  D Y Lin, L J Wei•Journal of the American…•1989

  Incluir item

• Adherence to Medication

  Lars Osterberg, Terrence F Blaschke et al.•New England Journal of Medicine•2005

  Incluir item

• Trends in Prescription Drug Expenditures by Medicaid Enrollees

  Jessica S Banthin, G Edward Miller•Medical Care•2006

  Incluir item